Abstract
Refractory pruritus associated with Essential Thrombocythemia (ET) is rare. Herein, we present the first report of resistant pruritus responsive to ruxolitinib in an ET patient with a calreticulin mutation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have